Cimetidine prevents recurrence and metastasis of colorectal cancer and its clinicl effects

doi:10.3877/cma.j.issn.1674-0793.2009.01.010

Abstract

Abstract:

Objective

To investigate the clinical effects of cimetidine for the treatment of colorectal cancer and the relationships with the expression of sialyl Lewis-X (SLeX) in colorectal carcinoma.

Methods

The expressions of SLeX in colorectal carcinoma (80 cases)were studied by microwave-labelled strept-avidin biotin immunohistochemical method.Seventy-three patients with positive expressions of SLeX were randomly allocated into two groups.The cimetidine group (43 cases)was given 200 mg per day of 5-fluorouracil orally together with 800 mg per day of cimetidine,while the control group (30 cases)received 5-fluorouracil alone.The treatment was initiated 3 weeks after the operation and terminated after one year for all patients.LFP chemotherapy was administrated for Duke's C patients.A mean follow-up term was (10.4±2.6)years.

Results

The total 10-year survival rate in cimetidine group was 83.7%,whereas that in control group was 50.0%.The 10-year survival rate of Duke's C patients in cimetidine group was 84.6%,whereas that in control group was 22.2%.The 10-year survival rate of patients with high SLeX expression (grade III)in cimetidine group was 92.3%,whereas that in control group was 29.4%.Hepatic metastasis in cimetidine group was 20.9%,whereas that in control group was 53.3%.The effects of cimetidine treatment as shown above parameters was remarkably significant (P＜0.05). In contrast, the 10-year survival rate of Duke's A+B patients in cimetidine group was 82.4%, whereas that in control group was 91.7%.The 10-year survival rate of patients with low SLeX expression (grade Ⅱ)in cimetidine group was 70.6%,whereas that in control group was 76.9%.Local recurrence in cimetidine group was 25.6%,whereas that in control group was 43.3%.The effects of cimetidine treatment as shown above parameters was not significant.

Conclusion

Cimetidine administration can dramatically improve patients'survival rate in advanced colorectal cancer patients with tumor cells ofhigh expressing levels ofSLeX.

Key words: Colorectalneoplasms, Neoplasmsmetastasis, SialylLewis-X, Cimetidine

Peizhong SHANG, Guo-hong JIA, Jian-jun MIAO, Li CUI, Yong-qing LI, Xiao-wu LI, Xi-qin ZHU, Xia LI, Huaping GU. Cimetidine prevents recurrence and metastasis of colorectal cancer and its clinicl effects[J]. Chinese Archives of General Surgery(Electronic Edition), 2009, 03(01): 35-40.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2009.01.010

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2009/V03/I01/35

Figures/Tables 4

References 20

1	尚培中,张金江,贾国洪,等.基质金属蛋白酶-2 和唾液酸化Lewis-X 在乳腺癌中的表达及其意义.中华乳腺病杂志:电子版, 2008, 2(2):177-183.
2	李小卫,丁彦青,蔡俊杰,等.唾液酸化的路易斯寡糖-X 抗原在结直肠癌细胞系LoVo、HT29 中的表达及其与转移潜能的相关性.中华病理学杂志,2000,29(2):119-122.
3	尚培中,谷化平,孙印臣.唾液酸化Lewis X 在大肠癌中的表达研究.中华普通外科杂志,2001,16(10):593-594.
4	Lefranc F,Yeaton P,Brotchi J,et al.Cimetidine,an unexpected anti-tumor agent,and its potential for the treatment of glioblastoma(Review).Int J Oncol,2006,28(5):1021-1030.
5	Matsumoto S, Imaeda Y, Umemoto S, et al. Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells.Br J Cancer,2002,86(2):161-167.
6	杨正安,纪宗正,周育民,等.西咪替丁对恶性肿瘤患者外周血T 淋巴细胞的影响.普外基础与临床杂志,1995,2(4):220-222.
7	闻勤生,张国治,孔宪涛,等.甲氰咪胍对胃癌患者白细胞介素2 和γ-干扰素的调节作用.中华肿瘤杂志,1994,16(4):299-301.
8	Chen AJ,Li Y,Yang GL, et al. Perioperative cimetidine administration enhances tumor infiltration lymphocytes and HLA-DR expression in colorectal cancer.Chinese-German J Clin Oncol,2006,5(1):49-53.
9	李太原,张海涛,端木尽忠.西咪替丁在体外对大肠癌细胞的敏感性.江西医学院学报,2006,46(6):26-28.
10	Kubota T, Fujiwara H, Ueda Y, et al. Cimetidine modulates the antigen presenting capacity of dendritic cells from colorectal cancer patients. British Journal of Cancer,2002,86(8):1257-1261.
11	Tomita K, Izumi K, Okabe S. Roxatidine-and cimetidine-induced angiogenesis inhibition suppresses growth of colon cancer implants in syngeneic mice. J Pharmacol Sci,2003,93(3):321-330.
12	Natori T,Sata M,Nagai R,et al.Cimetidine inhibits angiogenesis and suppresses tumor growth. Biomedicine＆Pharmacotherapy,2005,59(1):56-60.
13	Rajendra S, Mulcahy H, Patchett S, et al. The effect of H2 antagonists on proliferation and apoptosis in human colorectal cancer cell lines. Digestive Diseases and Sciences,2004,49(10):1634-1640.
14	谷化平, 尚培中, 倪灶荣. Sialyl Lewis-X,CD44v6 和E-cadherin 表达与肝细胞癌转移和预后的关系. 中华普通外科杂志, 2003, 18 (2):109-111.
15	尚培中,谷化平,孙印臣,等.大肠癌组织中唾液酸化Lewis X 和选择素P 联合检测的临床意义.中国全科医学,2002,5(11):873-875.
16	袁建寰,颜琳,夏婷,等.E-选择素及其配体SLe-X 与宫颈鳞癌淋巴结转移的关系.现代肿瘤医学,2005,13(2):197-198.
17	袁建寰,林静吟,夏婷,等.CD15s 与P-选择素在宫颈鳞状细胞癌的表达和意义.武汉大学学报：医学版,2006,27(1):44-46.
18	洪道显,陈火国,陈煜,等.大肠癌患者可溶性E-选择素及细胞内黏附分子-1 血清水平的意义.现代肿瘤医学,2006,14(12):1553-1555.
19	齐洪峰,李世拥,安萍,等.结直肠癌患者血清可溶性E 选择素的检测及其临床意义.解放军医学杂志,2006,31(9):858-859.
20	李小卫,刘平,丁彦青.Sialyl Lewis-X 抗原在大肠癌肝转移中的作用研究及临床意义.临床肿瘤学杂志,2006,11(4):269-273.

	治疗组(43例)	对照组(30例)	χ²值
性别
男	24	15	0.240
女	19	15
年龄（岁）
＜50	17	13	0.105
≥50	26	17
部位
结肠	25	20	0.543
直肠	18	10
肉眼类型
隆起型	4	4	0.294
溃疡型	36	25	0.002
浸润型	3	1	0.453
组织类型
高/中分化腺癌	30	17	1.323
低分化腺癌	7	7	0.567
黏液腺癌	6	6	0.470
Duke's分期
A	5	3	0.048
B	12	9	0.038
C	26	18	0.002

	治疗组(43例)	对照组(30例)	χ²值
性别
男	24	15	0.240
女	19	15
年龄（岁）
＜50	17	13	0.105
≥50	26	17
部位
结肠	25	20	0.543
直肠	18	10
肉眼类型
隆起型	4	4	0.294
溃疡型	36	25	0.002
浸润型	3	1	0.453
组织类型
高/中分化腺癌	30	17	1.323
低分化腺癌	7	7	0.567
黏液腺癌	6	6	0.470
Duke's分期
A	5	3	0.048
B	12	9	0.038
C	26	18	0.002

[1]	Xin-hui FU, Yan-hong DENG, Xin-juan FAN, Yan-xin LUO, Dian-ke CHEN, Lei WANG, Ping LAN, Huan-liang LIU, Jian-ping WANG. Detecting KRAS mutations in colorectal carcinoma patients with high resolution melting curve analy－sis [J]. Chinese Archives of General Surgery(Electronic Edition), 2009, 03(05): 14-16.
[2]	Yunzhi Dang, Jiao Yu, Shuhong Zhao, Long Jin, Xiaoyue Ren, Qing Wang. The expression of VASP in colorectal cancer and its relationship with metastasis [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2021, 10(03): 266-272.

Please choose a citation manager

Content to export